Fargesin
Cat. No. :YN482533
CAS No. :31008-19-2
86-020-82000279
sales@ubiochem.com
order@ubiochem.com| Product Name: | Fargesin |
| CAS NO.: | 31008-19-2 |
| Chemical Name: | |
| Synonyms: | |
| Molecular Weight: | 370.40 |
| Molecular Formula: | C₂₁H₂₂O₆ |
| SMILES: | COC1=CC=C([C@H]2OC[C@@]3([H])[C@H](C4=CC=C(OCO5)C5=C4)OC[C@]32[H])C=C1OC |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Transportation: | Room temperature in continental US; may vary elsewhere. |
| Description: | Fargesin is widely used in the treatment of managing rhinitis, inflammation, histamine, sinusitis, and headache; fargesin treatment can reduce SBP, cardiac hypertrophy, and Ang II and ET levels of hypertensive rats and increase NOS activity and NO level. Fargesin improves lipid and glucose metabolism in 3T3-L1 adipocytes and high-fat diet-induced obese mice by activating Akt and AMPK in WAT. Fargesin increases basal glucose uptake and GLUT4 translocation in L6 myotubes by activating the PI3 K-Akt pathway. Fargesin as a potential β1 adrenergic receptor antagonist protects the hearts against ischemia/reperfusion injury in rats via attenuating oxidative stress and apoptosis. Fargesin exerts anti-inflammatory effects in THP-1 monocytes by suppressing PKC-dependent AP-1 and NF-ĸB signaling. Fargesin can substantially reduce bone-resorbing activity of osteoclasts by inhibiting MMP-9 and cathepsin K activities and can inhibit tumor growth and cancer-mediated bone destruction in mice with MDA-MB-231 cells injected into calvarial tissues. |
| IC50&Target: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: | |
| References: |
TELL : +86-020-82000279
Add:Room 519, Block F, Guangzhou International Business Incubator, No.3 Lanyue Road, Science Town, Huangpu District, Guangzhou, China.
